BALTIMORE, MD--(Marketwired - Nov 12, 2015) - GrayBug, Inc., a venture-stage pharmaceutical company developing microparticle controlled release drug delivery technologies for the treatment of ocular diseases including wet age-related macular degeneration (AMD) and glaucoma, said that Jeffrey L. Cleland, PhD, GrayBug Interim Chief Executive Officer, will present a brief corporate overview at the Drug Delivery Company Showcase at 9:00 am PST today, November 12, during the Ophthalmology Innovation Summit (OIS) in Las Vegas, NV. 

The Ophthalmology Innovation Summit was created to facilitate meaningful interactions and business partnerships between physicians, entrepreneurs, investors and industry executives who are driving ophthalmic innovation. OIS addresses key issues -- both hurdles and opportunities while showcasing the most promising private ophthalmic companies. It is held just prior to the American Academy of Ophthalmology Annual Meeting, which begins on November 14, 2015 in Las Vegas.

About GrayBug, Inc.

GrayBug was founded in September 2011 as a spin-out of the Wilmer Eye Institute of the Johns Hopkins University School of Medicine. GrayBug is developing injectable controlled release technologies to reduce the frequency of ocular therapy to a few times per year (as few as twice per year). These technologies have solved the problems with tolerability and blockage of vision noted with many injectable sustained release ocular products. GrayBug is initially focused on developing its own products for the treatment of wet AMD and glaucoma. 

GrayBug's technologies were co-developed by GrayBug founder, Justin Hanes, PhD, who is the Lewis J. Ort Professor of Ophthalmology at the Wilmer Eye Institute of the Johns Hopkins University, in collaboration with GrayBug cofounders, and leading ophthalmology clinician-scientists from the Wilmer Eye Institute Peter A. Campochiaro, MD, and Peter J. McDonnell, MD. The technologies were licensed from Johns Hopkins University. For more information, please visit

Contact Information:

GrayBug, Inc. Corporate
Jeffrey L. Cleland, PhD

GrayBug, Inc. Media
Debra Bannister